A Phase II Trial of Pazopanib in Von Hippel-Lindau Syndrome.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Von Hippel-Lindau disease
- Focus Therapeutic Use
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 14 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 20 Jan 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov.